Brief: Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)
21/04/2026 14:05
Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS COMPLETES FEDERAL DISPUTE RESOLUTION (FDR) MEETING WITH FDA FOR ONS-5010/LYTENAVA™ (BEVACIZUMAB-VIKG) OUTLOOK THERAPEUTICS INC - EXPECTS FDA FEEDBACK IN MAY 2026 Source text: ID:nGNX6JXv5G Further company coverage: OTLK.O
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce